May 28, 2026 09:10AM
May 28, 2026 09:10AM
May 22, 2026 07:00AM
May 19, 2026 07:00AM
May 19, 2026 07:00AM
May 13, 2026 04:01PM
May 13, 2026 04:01PM Medicenna Announces the Launch of a Marketed Public Offering of Securities
May 12, 2026 07:00AM
Apr 30, 2026 07:30AM
Apr 21, 2026 07:30AM
Apr 14, 2026 07:30AM
Feb 13, 2026 08:09AM
Dec 9, 2025 05:04PM
Nov 13, 2025 07:00AM Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
Oct 23, 2025 05:12PM
Oct 1, 2025 09:35AM
Apr 22, 2025 07:00AM
Apr 1, 2025 07:00AM
Mar 26, 2025 07:00AM
Feb 25, 2025 07:05AM
Feb 25, 2025 07:00AM Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference a
Feb 13, 2025 10:28AM
Feb 5, 2025 07:00AM
Dec 13, 2024 08:30AM
Dec 5, 2024 07:35AM
Nov 27, 2024 07:02AM
Nov 27, 2024 07:00AM
Nov 25, 2024 07:30AM Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)
Nov 15, 2024 07:30AM
Nov 13, 2024 07:00AM
Nov 11, 2024 07:00AM
Nov 8, 2024 10:00AM
Oct 4, 2024 09:07AM
Sep 26, 2024 05:00PM
Sep 9, 2024 07:32AM Medicenna Presents Preclinical Results from its IL-2 Super-Antagonist and Anti-PD1-IL-2 BiSKIT Programs at The Promise of Interleukin-2 Therapy Conference
Sep 5, 2024 07:00AM
Aug 27, 2024 07:00AM
Aug 15, 2024 07:31AM
Aug 15, 2024 07:30AM
Aug 1, 2024 07:00AM
Jun 27, 2024 08:18AM
Jun 26, 2024 07:47AM Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe
Jun 3, 2024 08:00AM
May 31, 2024 09:29AM
May 22, 2024 07:00AM
May 13, 2024 07:00AM
Apr 24, 2024 10:05AM
Apr 10, 2024 06:32AM
Apr 10, 2024 06:30AM Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the America
Apr 9, 2024 04:30PM

322,215 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All